NeoStem is developing an immunotherapeutic applicable across multiple solid tumors with Special Protocol Assessment, Fast Track and Orphan Drug designations for a Phase 3 program in metastatic melanoma and near-term development milestones.
Enhancingthe body’s healing response
Rebalancingthe immune system
Innovatingdevelopment and manufacturing of cell-based therapies
NeoStem’s subsidiary, PCT, provides development manufacturing capabilities to the cell therapy industry while supporting the development of NeoStem’s proprietary cell therapy products.
News + EventsNeoStem Prices $25,000,000 Public Offering of Common Stock May 27, 2015 - Learn MoreNeoStem Announces Dr. Merrick Ross of MD Anderson Cancer Center as Lead Principal Investigator for Pivotal Phase 3 Trial for Metastatic Melanoma May 26, 2015 - Learn MoreTurning Cancer Against Itself: Major Grant Advances Pioneering Melanoma Therapy at NeoStem May 21, 2015 - Learn More
Dear NeoStem Shareholders, As you might imagine, the first two months of my tenure as the Chief Executive O.... Read More
After an extensive search, it is with great pleasure that I have the opportunity today to introduce Dr. Dav.... Read More